GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (LTS:0K0K) » Definitions » Return-on-Tangible-Equity

Meridian Bioscience (LTS:0K0K) Return-on-Tangible-Equity : 13.06% (As of Sep. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Meridian Bioscience Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Meridian Bioscience's annualized net income for the quarter that ended in Sep. 2022 was $22.8 Mil. Meridian Bioscience's average shareholder tangible equity for the quarter that ended in Sep. 2022 was $174.7 Mil. Therefore, Meridian Bioscience's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2022 was 13.06%.

The historical rank and industry rank for Meridian Bioscience's Return-on-Tangible-Equity or its related term are showing as below:

LTS:0K0K's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -0.81
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Meridian Bioscience Return-on-Tangible-Equity Historical Data

The historical data trend for Meridian Bioscience's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Return-on-Tangible-Equity Chart

Meridian Bioscience Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.70 35.04 100.70 79.46 27.65

Meridian Bioscience Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.52 44.09 69.62 -16.62 13.06

Competitive Comparison of Meridian Bioscience's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, Meridian Bioscience's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meridian Bioscience's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Meridian Bioscience's Return-on-Tangible-Equity falls into.



Meridian Bioscience Return-on-Tangible-Equity Calculation

Meridian Bioscience's annualized Return-on-Tangible-Equity for the fiscal year that ended in Sep. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Sep. 2022 )  (A: Sep. 2021 )(A: Sep. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Sep. 2022 )  (A: Sep. 2021 )(A: Sep. 2022 )
=42.459/( (129.483+177.628 )/ 2 )
=42.459/153.5555
=27.65 %

Meridian Bioscience's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2022 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2022 )  (Q: Jun. 2022 )(Q: Sep. 2022 )
=22.82/( (171.739+177.628)/ 2 )
=22.82/174.6835
=13.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Meridian Bioscience  (LTS:0K0K) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Meridian Bioscience Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Meridian Bioscience (LTS:0K0K) Business Description

Traded in Other Exchanges
N/A
Address
3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Meridian Bioscience (LTS:0K0K) Headlines

No Headlines